Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28994161 | 0.94 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1HDAC4 | |
| SCHEMBL29060516 | 0.89 | OPRM1 (0.59) | OPRM1OPRD1OPRK1OPRL1HDAC4 | |
| SCHEMBL29484741 | 0.80 | MEN1 (0.41) | HDAC4ALDH1A1MAPTSMN1; SMN2SIGMAR1 | |
| SCHEMBL17733195 | 0.80 | MEN1 (0.41) | HDAC4ALDH1A1MAPTSMN1; SMN2SIGMAR1 | |
| SCHEMBL6058582 | 0.80 | MEN1 (0.41) | HDAC4ALDH1A1MAPTSMN1; SMN2SIGMAR1 | |
| SCHEMBL2270935 | 0.80 | SIGMAR1 (0.62) | OPRM1OPRD1OPRK1OPRL1HDAC4 | |
| SCHEMBL12862966 | 0.80 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1HDAC4 | |
| SCHEMBL7101793 | 0.79 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1SMN1; SMN2 | |
| SCHEMBL632646 | 0.79 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8175707 | 0.79 | SIGMAR1 (0.60) | OPRM1OPRD1OPRK1OPRL1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472446-B2 | Composition, resin mold, photo imprinting method, method for manufacturing optical element, and method for manufacturing electronic element | TOYO GOSEI CO., LTD. (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20160017074-A1 | COMPOSITION, RESIN MOLD, PHOTO IMPRINTING METHOD, METHOD FOR MANUFACTURING OPTICAL ELEMENT, AND METHOD FOR MANUFACTURING ELECTRONIC ELEMENT | TOYO GOSEI CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-8911543-B2 | Phenylcyclohexanol derivatives as wax modifiers and gelators | XEROX CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140165873-A1 | Phenylcyclohexanol Derivatives As Wax Modifiers And Gelators | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | disclosed |
| US-7022739-B2 | Substituted 1-aminobutan-3-ol compounds | GRUENENTHAL GMBH (DE) | 2006-04-04 | — | — | US | disclosed |
| US-4111917-A | POLYURETHANES | W. R. GRACE & CO. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140165873-A1 | Phenylcyclohexanol Derivatives As Wax Modifiers And Gelators | NR1H3, RXRG, NR1H2 | OPRM1 610/4885OPRD1 273/4885OPRK1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.